Kazia Therapeutics (NASDAQ:KZIA) Stock Price Down 3.6%

Kazia Therapeutics Limited (NASDAQ:KZIA)’s stock price fell 3.6% during mid-day trading on Tuesday . The stock traded as low as $0.32 and last traded at $0.32. 238,340 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 4,918,213 shares. The stock had previously closed at $0.33.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Kazia Therapeutics in a report on Friday, July 12th.

Kazia Therapeutics Price Performance

The business’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $0.34.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Platinum Investment Management Ltd. acquired a new position in Kazia Therapeutics Limited (NASDAQ:KZIA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,821,887 shares of the company’s stock, valued at approximately $801,000. Platinum Investment Management Ltd. owned 11.15% of Kazia Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 30.89% of the company’s stock.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.